Login to Your Account



Deals And M&A NEWS

HONG KONG – 3SBio Inc., based in China's northeast city, Shenyang, entered into a licensing agreement with Korean biotech company Pharmabcine Inc. to develop, manufacture and market the anti-vascular endothelial growth factor receptor 2 (VEGFR2) and kinase insert domain receptor antibody, tanibirumab. The deal could benefit up to 1 million cancer patients in China each year.

Pfizer Inc. is turbocharging Merck KGaA's development of its programmed death ligand 1 inhibitor MSB0010718C in a global deal worth $850 million up front and about $2 billion more in regulatory and commercial milestones.

SHANGHAI – Ascletis Inc., a Chinese biotech with deep pockets, has obtained exclusive China rights for PPI-668, an NS5A inhibitor of the hepatitis C virus (HCV), from the San Francisco-based Presidio Pharmaceuticals Inc.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: